Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Armeanu Ebinger, Sorin ^a   Wenz, Julia ^a   Seitz, Guido ^a   Leuschner, Ivo ^b   Handgretinger, Rupert ^a   Mau Holzmann, Ulrike A ^c   Bonin, Michael ^c   Sipos, Bence ^c   Fuchs, Jörg ^a   Warmann, Steven W ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; CARBOPLATIN; CISPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; ETOPOSIDE; GLYCOGEN SYNTHASE KINASE 3; GLYPICAN 3; IRINOTECAN; UVOMORULIN; VIMENTIN; CYTOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CELL CULTURE; CELL NUCLEUS; CHILD; CHROMOSOME ANALYSIS; CHROMOSOME MAP; DRUG SENSITIVITY; EXON; GENE DOSAGE; GROWTH INHIBITION; HC AFW1 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRESCHOOL CHILD; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR XENOGRAFT; ANIMAL; ARTICLE; CELL SEPARATION; CELL TRANSFORMATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE;

MUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SEPARATION; CELL TRANSFORMATION, NEOPLASTIC; CHILD, PRESCHOOL; CYTOSTATIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; PHENOTYPE;

EID: 84861636323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038223     Document Type: Review

References (33)

1. Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford E, et al. (2002) Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 20: 2798-2804.
2. Czauderna P, (2002) Adult type vs. Childhood hepatocellular carcinoma-are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 39: 519-523.
3. Kim H, Lee MJ, Kim MR, Chung IP, Kim YM, et al. (2000) Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver 20: 173-178.
4. Gupta AA, Gerstle JT, Ng V, Wong A, Fecteau A, et al. (2011) Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatr Blood Cancer 56: 1013-1018.
5. Doi I, (1976) Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 67: 1-10.
6. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, et al. (1996) Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74: 809-818.
7. Chen TT, Rakheja D, Hung JY, Hornsby PJ, Tabaczewski P, et al. (2009) Establishment and characterization of a cancer cell line derived from an aggressive childhood liver tumor. Pediatr Blood Cancer 53: 1040-1047.
8. Brummendorf TH, Rufer N, Holyoake TL, Maciejewski J, Barnett MJ, et al. (2001) Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann N Y Acad Sci 938: 293-303.
9. Fuchs J, Schmidt D, Pietsch T, Miller K, von Schweinitz D, (1996) Successful transplantation of human hepatoblastoma into immunodeficient mice. J Pediatr Surg 31: 1241-1246.
10. Braeuning A, Sanna R, Huelsken J, Schwarz M, (2009) Inducibility of drug-metabolizing enzymes by xenobiotics in mice with liver-specific knockout of Ctnnb1. Drug Metab Dispos 37: 1138-1145.
11. Schmidt A, Braeuning A, Ruck P, Seitz G, Armeanu-Ebinger S, et al. (2011) Differential expression of Glutamine synthetase and Cytochrome P450 isoforms in human hepatoblastoma. Toxicology 281: 7-14.
12. Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, et al. (2011) Development of a drug resistance model for hepatoblastoma. Int J Oncol 38: 447-454.
13. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, et al. (2010) Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28: 649-660.
14. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB, (1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282: 615-616.
15. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J, (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858-3863.
16. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, et al. (1995) Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 62: 276-282.
17. Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, et al. (2009) Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 40: 843-853.
18. Lopez-Terrada D, Cheung SW, Finegold MJ, Knowles BB, (2009) HepG2 is a hepatoblastoma-derived cell line. Hum Pathol 40: 1512-1515.
19. Wang LL, Filippi RZ, Zurakowski D, Archibald T, Vargas SO, et al. (2010) Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. Am J Surg Pathol 34: 287-299.
20. Prokurat A, Kluge P, Kosciesza A, Perek D, Kappeler A, et al. (2002) Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 39: 510-518.
21. Crawley JJ, Furge KA, (2002) Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol 3: research0075.1-research0075.8.
22. Scheil S, Hagen S, Bruderlein S, Leuschner I, Behnisch W, et al. (2003) Two novel in vitro human hepatoblastoma models, HepU1 and HepU2, are highly characteristic of fetal-embryonal differentiation in hepatoblastoma. Int J Cancer 105: 347-352.
23. Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, et al. (2006) Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44: 1012-1024.
24. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, et al. (1999) Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 18: 4044-4046.
25. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, et al. (1999) Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 59: 269-273.
26. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, et al. (1998) Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 58: 2524-2527.
27. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, et al. (1999) Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155: 703-710.
28. Whittaker S, Marais R, Zhu AX, (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005.
29. Warmann SW, Frank H, Heitmann H, Ruck P, Herberts T, et al. (2008) Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res 144: 43-48.
30. Zhu Z, Hao X, Yan M, Yao M, Ge C, et al. (2010) Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 126: 2067-2078.
31. Lee TK, Lau TC, Ng IO, (2002) Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 49: 78-86.
32. Yu CW, Li KK, Pang SK, Au-Yeung SC, Ho YP, (2006) Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane. Bioorg Med Chem Lett 16: 1686-1691.
33. Konnikova L, Simeone MC, Kruger MM, Kotecki M, Cochran BH, (2005) Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 65: 6516-6520.